Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.
about
IMP dehydrogenase: structure, mechanism, and inhibition.Preferential use of central metabolism in vivo reveals a nutritional basis for polymicrobial infectionCarbon metabolism of enterobacterial human pathogens growing in epithelial colorectal adenocarcinoma (Caco-2) cellsThe antibiotic potential of prokaryotic IMP dehydrogenase inhibitorsAttenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection.Phenotypic and genotypic characterization of serologically atypical strains of Shigella flexneri type 4 isolated in Dhaka, Bangladesh.Strategy for cross-protection among Shigella flexneri serotypesShigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.Parameters underlying successful protection with live attenuated mutants in experimental shigellosisConstitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.Identification of Actinobacillus suis genes essential for the colonization of the upper respiratory tract of swine.Construction of in-frame aroA deletion mutants of Mannheimia haemolytica, Pasteurella multocida, and Haemophilus somnus by using a new temperature-sensitive plasmid.Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain.Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutantsAttenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats.Use of a novel approach, termed island probing, identifies the Shigella flexneri she pathogenicity island which encodes a homolog of the immunoglobulin A protease-like family of proteins.Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit.Enteric pathogens as vaccine vectors for foreign antigen deliverySignature-tagged mutagenesis of Vibrio vulnificus.Regulation of purine biosynthesis by a eukaryotic-type kinase in Streptococcus agalactiaeClinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.De Novo Guanine Biosynthesis but Not the Riboswitch-Regulated Purine Salvage Pathway Is Required for Staphylococcus aureus Infection In VivoGuaA and GuaB are essential for Borrelia burgdorferi survival in the tick-mouse infection cycle.Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.Altering trends in the dominance of Shigella flexneri serotypes and emergence of serologically atypical S. flexneri strains in Dhaka, Bangladesh.Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants.Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells.Identification of Actinobacillus pleuropneumoniae genes important for survival during infection in its natural hostGene replacement and quantitative mass spectrometry approaches validate guanosine monophosphate synthetase as essential for Mycobacterium tuberculosis growth.
P2860
Q24642299-1F764B3F-FE0D-4D0C-AA4D-082C3F9EF9C1Q27321660-D2655AB0-2D14-48CA-9056-BF3A7F81FFB5Q28473899-2A6A686E-E285-41A7-AC4B-B9B933AA23F5Q30356398-503E7C55-1FA8-49DC-8E24-7EDDC8198493Q33597022-5D246767-525B-4769-A815-9AE760CAA4C6Q33801151-041DDB34-0FCD-45F8-A578-EAC9FBFE26B2Q33962691-A122721C-4742-46C3-964F-16B4E512EB2FQ34000330-0C133D98-4427-46AD-B642-587BDA4F6A82Q34003433-2EAA3726-6ADB-441A-A5CE-CD415796B7C6Q34006071-D44B8F35-1042-4669-9734-1B93BF59388FQ34007802-8154AE16-7DDC-4179-8D1A-D97996168F79Q34008449-58B49323-6EF5-4E95-9B2B-C79EB30C097CQ34033349-AA1AAD49-FE5A-47BB-95FD-E0BB4210433DQ34143390-062AC122-1A1F-4865-967C-3D609CC03082Q34716080-FDF45EBC-8CEA-4501-BC91-A3A5003A9168Q34941041-BFC36899-4FB2-4F0D-89DF-733019C1D46EQ34976024-37802DD3-3323-4260-ADF9-DE42C945D4A3Q35557903-385E3071-1059-4C8E-B4C7-A24F662B75FAQ35598035-CDFCD92F-59EC-4929-96BB-35AEC2300A46Q35896020-736E73AA-3528-4880-A44E-EA78256E17C5Q35924128-89BCFB78-CB56-4FBA-A5F9-16D4772B747CQ36629400-AC56B0ED-D955-4787-9EFE-B2FC5E1FAE7DQ36844719-9B52AAD5-2234-46DD-9D65-4A3914A203F0Q37073234-89826A10-DFC2-44F9-978C-176765921FA3Q37365218-3C31A8CE-172F-4A2B-8CA1-53CF18B3D8D4Q38776163-72333D66-0256-4EB5-98C9-260FDBA623FAQ39466650-89E5B3AB-432D-4E15-8EED-1FD7BD625AE0Q39519924-525D3173-40BC-44D4-9B63-A05312E0AB55Q39569905-22B0F77A-92F9-4D56-9C3B-6E115D8C4B73Q39610195-B899B796-6B48-48BF-8F2E-466D6090BE55Q39776783-A8375853-DB6F-445A-807C-AB9B5955762FQ47131278-C07F8FD3-97B3-40E6-B33A-FF24C36D2F75
P2860
Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Engineered deltaguaB-A deltavi ...... efficacy as a mucosal vaccine.
@ast
Engineered deltaguaB-A deltavi ...... efficacy as a mucosal vaccine.
@en
type
label
Engineered deltaguaB-A deltavi ...... efficacy as a mucosal vaccine.
@ast
Engineered deltaguaB-A deltavi ...... efficacy as a mucosal vaccine.
@en
prefLabel
Engineered deltaguaB-A deltavi ...... efficacy as a mucosal vaccine.
@ast
Engineered deltaguaB-A deltavi ...... efficacy as a mucosal vaccine.
@en
P2093
P2860
P1476
Engineered deltaguaB-A deltavi ...... efficacy as a mucosal vaccine.
@en
P2093
C Lauderbaugh
F R Noriega
G Losonsky
M M Levine
P2860
P304
P407
P577
1996-08-01T00:00:00Z